Clinical studies of lactobacilli showing efficacy for treatment of vaginal disorders
| Bacteria | Dose | Pathology | Ref. (Design) |
|---|---|---|---|
| L. plantarum P17630 | >108 CFU | Acute vulvovaginal candidiasis | 97(retrospective comparative study) |
| L. rhamnosus GR-1 L. fermentum RC-14 | >109 CFU (of each) | Potential pathogenic bacteria and yeast vagina colonisation | 102(open study) |
| Kramegin® (L. acidophilus + lactic acid and Krameria triandra extract) | Not stated | Abnormal cervical cytology | 103(open study) |
| Ellen AB® (L. gasseri LN40, L. fermentum LN99, L. casei subsp rhamnosus LN113 and P. acidilactici LN23 + an inert carrying matrix of maltodextrin and magnesium stearate) | 108–10 CFU (total) Not stated | Bacterial vaginosis and vulvovaginal candidiasis | 104(randomised double-blind placebo-controlled study) |
| L. fermentum LF10 L. acidophilus LA02 + Arabinogalactan + Fructooligosaccharides | 0.4×109 CFU (of each) 340 mg 241 mg | Recurrent vulvovaginal candidiasis | 105(clinical study) |
| L. fermentum LF15 L. plantarum LP01 + Tara gum | 0.4×109 CFU (of each) 50 mg | Bacterial vaginosis | 106(pilot study) |
| Florisia® [L. brevis (CD2), L. salivarius subsp salicinius (FV2) and L. plantarum (FV9)] | 109 CFU (total) | Bacterial vaginosis | 107(randomised, double-blind, placebo-controlled study) |
| L. rhamnosus GR-1 L. reuteri RC-14 | 2.5×109 CFU (of each) | Vaginal flora overgrowth | 108(randomised, double-blind, placebo-controlled study) |
| EcoVag® [L. gasseri (Lba EB01-DSM 14869) and L. Rhamnosus (Lbp PB01-DSM 14870)] | 108–9 CFU (of each) | Bacterial vaginosis | 109(double-blind, randomised, placebo-controlled study) |